• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Aurora Cannabis upgraded by Canaccord Genuity

    9/21/22 9:02:55 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACB alert in real time by email
    Canaccord Genuity upgraded Aurora Cannabis from Sell to Hold
    Get the next $ACB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACB

    DatePrice TargetRatingAnalyst
    12/11/2024Buy
    TD Cowen
    2/9/2024Hold → Buy
    Canaccord Genuity
    9/21/2022Sell → Hold
    Canaccord Genuity
    6/24/2022Neutral → Overweight
    Cantor Fitzgerald
    6/6/2022Sell → Hold
    Stifel
    11/10/2021$9.60 → $10.75Neutral
    Cantor Fitzgerald
    10/28/2021$9.50 → $9.60Neutral
    Cantor Fitzgerald
    10/5/2021$8.30 → $9.50Neutral
    Cantor Fitzgerald
    More analyst ratings

    $ACB
    SEC Filings

    View All

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    11/5/25 7:25:30 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    11/5/25 7:16:32 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    10/22/25 6:02:08 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Aurora Cannabis

    TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy

    12/11/24 10:35:16 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy

    2/9/24 6:09:16 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Aurora Cannabis from Sell to Hold

    9/21/22 9:02:55 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aurora Cannabis Announces Fiscal 2026 Second Quarter Results

    Expands YoY Global Medical Cannabis Net Revenue1 by 15% to Record $70.5 millionIncreases International Medical Cannabis Net Revenue1 by 22% to Record $42.7 million, with leadership positions across key marketsDelivers Adjusted EBITDA1 growth of 52%, reaching $15.4 million  Maintains Strong Balance Sheet with $141.9 million of Cash and Debt-Free Cannabis Business2NASDAQ | TSX: ACB EDMONTON, AB, Nov. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2026 period ending September 30, 2025.

    11/5/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis to Host Second Quarter 2026 Investor Conference Call

    NASDAQ | TSX: ACB EDMONTON, AB, Oct. 22, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its second quarter 2026 on Wednesday, November 5, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the second quarter 2026 before the opening of markets that same day. Conference Call Details DATE: Wednesday, November 5, 2025 TIME: 8:00 a.m. Easte

    10/22/25 5:15:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Announces Investment into German Manufacturing Facility

    NASDAQ | TSX: ACB Facility investment includes adopting the company's unmatched global manufacturing practices for superior cannabis production and quality  EDMONTON, AB, Sept. 18, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, announces an investment over five years into operational upgrades at its EU-GMP manufacturing facility in Leuna, Germany. Building on best practices proven at Aurora's Canadian facilities, these improvements will increase flower growth capacity, product quality and drive cost efficiency.

    9/18/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Financials

    Live finance-specific insights

    View All

    Aurora Cannabis Announces Fiscal 2026 Second Quarter Results

    Expands YoY Global Medical Cannabis Net Revenue1 by 15% to Record $70.5 millionIncreases International Medical Cannabis Net Revenue1 by 22% to Record $42.7 million, with leadership positions across key marketsDelivers Adjusted EBITDA1 growth of 52%, reaching $15.4 million  Maintains Strong Balance Sheet with $141.9 million of Cash and Debt-Free Cannabis Business2NASDAQ | TSX: ACB EDMONTON, AB, Nov. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2026 period ending September 30, 2025.

    11/5/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis to Host Second Quarter 2026 Investor Conference Call

    NASDAQ | TSX: ACB EDMONTON, AB, Oct. 22, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its second quarter 2026 on Wednesday, November 5, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the second quarter 2026 before the opening of markets that same day. Conference Call Details DATE: Wednesday, November 5, 2025 TIME: 8:00 a.m. Easte

    10/22/25 5:15:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora to Participate in Canaccord Genuity 45th Annual Growth Conference

    Canada's Largest Medical Cannabis Company to Discuss Strategy, Industry Trends, and Long-Term Growth Outlook EDMONTON, ALBERTA, Aug. 7, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, will participate in Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat on August 13th at 1:30pm EST and conduct one-on-one meetings with investors throughout the day. The discussion will cover Aurora's strategic direction, recen

    8/7/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

    SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

    2/14/23 11:28:04 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Aurora Cannabis Inc.

    SC 13G - AURORA CANNABIS INC (0001683541) (Subject)

    6/1/22 10:14:29 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

    SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

    2/14/22 3:54:29 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Leadership Updates

    Live Leadership Updates

    View All

    Aurora Cannabis Inc. Announces Results of 2025 Annual General and Special Meeting

    NASDAQ | TSX: ACB EDMONTON, AB, Aug. 8, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held Friday August 8, 2025 by virtual webcast. The total number of shares represented by shareholders present in person (virtually) and by proxy at the Meeting was 17,736,521 common shares, representing 31.53% of Aurora's issued and outstanding common shares as of the record date.

    8/8/25 5:00:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Rubicon Organics Announces Appointment of Glen Ibbott as Interim CFO

    VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics" or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Interim Chief Financial Officer. Janis Risbin, current CFO, will be stepping away from her full-time role effective today. She will remain in an advisory role over the next few months to ensure a smooth transition of responsibilities to Mr. Ibbott. "Glen's leadership at Aurora C

    5/15/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora CEO Miguel Martin takes on additional role as Executive Chairman of Board of Directors

    NASDAQ | TSX: ACB Outgoing Chairman Ron Funk appointed Lead Independent Director, as part of Board leadership transition EDMONTON, AB, Sept. 20, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced the appointments of CEO Miguel Martin to the additional role of Executive Chairman and outgoing Chairman Ron Funk as Lead Independent Director. Both appointments follow unanimous votes by Aurora's Board and are effective immediately. Mr. Martin has served as Chief Executiv

    9/20/24 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care